Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study

BACKGROUND: Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin(®) is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase. METHODS: This phase II trial included patients...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Ann Oncol
Hoofdauteurs: Toulmonde, M., Le Cesne, A., Piperno-Neumann, S., Penel, N., Chevreau, C., Duffaud, F., Bellera, C., Italiano, A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2015
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4478976/
https://ncbi.nlm.nih.gov/pubmed/26041763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv195
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items